| Line Item | 2026-01-31 | Y/Y |
|---|---|---|
| Revenue | $702.3M | +30.8% |
| Cost of Revenue | $201.8M | +18.8% |
| Gross Profit | $500.5M | +36.4% |
| R&D Expense | $151.2M | +23.6% |
| SG&A Expense | $203.4M | +52.3% |
| Operating Income | -$196.9M | -82.9% |
| Pre-tax Income | -$395.9M | -130.8% |
| Income Tax | $2.1M | -78.0% |
| Net Income | -$398.0M |
| Line Item | 2026-01-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $583.5M | +270.1% |
| Short-term Investments | $157.0M | — |
| Accounts Receivable | $215.9M | +16.8% |
| Current Assets | $1.31B | +89.7% |
| Total Assets | $1.71B | +57.6% |
| Current Liabilities | $320.9M | -28.0% |
| Long-term Debt | $124.8M | -79.8% |
| Line Item | 2026-01-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $33.7M | +166.8% |
| Capital Expenditures | $917K | -7.7% |
| Investing Cash Flow | -$203.0M | -552.5% |
| Financing Cash Flow | $519.9M | +889.3% |
| Free Cash Flow | $32.8M | +163.7% |
| -119.8% |
| EPS (Basic) | -$4.07 | -1.8% |
| EPS (Diluted) | -$4.07 | -1.8% |
| Total Liabilities |
| $500.7M |
| -48.4% |
| Stockholders' Equity | $1.21B | +201.8% |